198 related articles for article (PubMed ID: 36509287)
1. A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.
Bordoloi D; Bhojnagarwala PS; Perales-Puchalt A; Kulkarni AJ; Zhu X; Liaw K; O'Connell RP; Park DH; Kulp DW; Zhang R; Weiner DB
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509287
[TBL] [Abstract][Full Text] [Related]
2. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
Perales-Puchalt A; Svoronos N; Rutkowski MR; Allegrezza MJ; Tesone AJ; Payne KK; Wickramasinghe J; Nguyen JM; O'Brien SW; Gumireddy K; Huang Q; Cadungog MG; Connolly DC; Tchou J; Curiel TJ; Conejo-Garcia JR
Clin Cancer Res; 2017 Jan; 23(2):441-453. PubMed ID: 27435394
[TBL] [Abstract][Full Text] [Related]
3. Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.
Urbanska K; Stashwick C; Poussin M; Powell DJ
Cancer Immunol Res; 2015 Oct; 3(10):1130-7. PubMed ID: 26112923
[TBL] [Abstract][Full Text] [Related]
4. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers.
Bordoloi D; Kulkarni AJ; Adeniji OS; Pampena MB; Bhojnagarwala PS; Zhao S; Ionescu C; Perales-Puchalt A; Parzych EM; Zhu X; Ali AR; Cassel J; Zhang R; Betts MR; Abdel-Mohsen M; Weiner DB
Sci Adv; 2023 Nov; 9(44):eadh4379. PubMed ID: 37910620
[TBL] [Abstract][Full Text] [Related]
5. Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.
Perales-Puchalt A; Wojtak K; Duperret EK; Yang X; Slager AM; Yan J; Muthumani K; Montaner LJ; Weiner DB
Mol Ther; 2019 Feb; 27(2):314-325. PubMed ID: 30554854
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
7. Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype.
Cheung J; Lokman NA; Abraham RD; Macpherson AM; Lee E; Grutzner F; Ghinea N; Oehler MK; Ricciardelli C
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374698
[TBL] [Abstract][Full Text] [Related]
8. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
[TBL] [Abstract][Full Text] [Related]
9. Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?
Papadimitriou K; Kountourakis P; Kottorou AE; Antonacopoulou AG; Rolfo C; Peeters M; Kalofonos HP
Mol Diagn Ther; 2016 Dec; 20(6):523-530. PubMed ID: 27392476
[TBL] [Abstract][Full Text] [Related]
10. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
Heublein S; Mayr D; Vrekoussis T; Friese K; Hofmann SS; Jeschke U; Lenhard M
PLoS One; 2013; 8(8):e71791. PubMed ID: 23951246
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
12. PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging.
Hong H; Yan Y; Shi S; Graves SA; Krasteva LK; Nickles RJ; Yang M; Cai W
Mol Pharm; 2015 Feb; 12(2):403-10. PubMed ID: 25581441
[TBL] [Abstract][Full Text] [Related]
13. Vascular Endothelial FSH Receptor, a Target of Interest for Cancer Therapy.
Ghinea N
Endocrinology; 2018 Sep; 159(9):3268-3274. PubMed ID: 30113652
[TBL] [Abstract][Full Text] [Related]
14. BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control.
McGray AJR; Chiello JL; Tsuji T; Long M; Maraszek K; Gaulin N; Rosario SR; Hess SM; Abrams SI; Kozbor D; Odunsi K; Zsiros E
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37647218
[TBL] [Abstract][Full Text] [Related]
15. Expression Levels of Follicle-Stimulating Hormone Receptor and Implication in Diagnostic and Therapeutic Strategy of Ovarian Cancer.
Wei S; Lai L; Yang J; Zhuandi G
Oncol Res Treat; 2018; 41(10):651-654. PubMed ID: 30145593
[TBL] [Abstract][Full Text] [Related]
16. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.
Zheng W; Lu JJ; Luo F; Zheng Y; Feng Yj; Felix JC; Lauchlan SC; Pike MC
Gynecol Oncol; 2000 Jan; 76(1):80-8. PubMed ID: 10620446
[TBL] [Abstract][Full Text] [Related]
17. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
18. No activating mutations of FSH receptor in four children with ovarian juvenile granulosa cell tumors and the association of these tumors with central precocious puberty.
Bas F; Pescovitz OH; Steinmetz R
J Pediatr Adolesc Gynecol; 2009 Jun; 22(3):173-9. PubMed ID: 19539204
[TBL] [Abstract][Full Text] [Related]
19. A novel follicle-stimulating hormone receptor mutation causing primary ovarian failure: a fertility application of whole exome sequencing.
Bramble MS; Goldstein EH; Lipson A; Ngun T; Eskin A; Gosschalk JE; Roach L; Vashist N; Barseghyan H; Lee E; Arboleda VA; Vaiman D; Yuksel Z; Fellous M; Vilain E
Hum Reprod; 2016 Apr; 31(4):905-14. PubMed ID: 26911863
[TBL] [Abstract][Full Text] [Related]
20. Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients.
Deuster E; Mayr D; Hester A; Kolben T; Zeder-Göß C; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31212758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
